5.3 | | Spry2 | 'hepatocyte-derived proliferative ducts (hepPDs)' vs 'hepatocyte' | cell type | Transcription profiling by high throughput sequencing of hepatocyte-derived progenitors cells in a mouse model of oval cell activation |
-4.3 | | Spry2 | 'ABIN1[D485N] knock-in' vs 'wild type genotype' in 'neutrophil' | cell type, genotype | RNA-seq of inflammatory monocytes, patrolling monocytes and neutrophils in wild type and ABIN1[D485N] mice |
4.2 | | Spry2 | 'adult definitive erythroid cell' vs 'primitive erythroid cell' in 'mix of orthochromatic and polychromatophilic erythroblast' | cell type, phenotype | Transcription profiling by array of differentiating primary primitive and definitive mouse red blood cells |
3.4 | | Spry2 | 'Egr2 and Egr3 knockout' vs 'Egr2-GFP knockin; Egr2-GFP high' in 'CD4-positive T cell' | cell type, genotype, phenotype | RNAseq analysis of CD4 and CD8 T cells in response to vaccinia virus infection |
3.3 | | Spry2 | 'Influenza A virus' vs 'none' | infect | RNA-seq of mouse alveolar macrophages from control and Influenza A virus infected animals |
3.2 | | Spry2 | '4 hours after hCG treatment' vs 'control' in 'wild type' | genotype, treatment | The ISWI ATPase Snf2L is required for superovulation and regulates Fgl2 in differentiating mouse granulosa cells |
3.1 | | Spry2 | 'adult definitive erythroid cell' vs 'primitive erythroid cell' in 'basophilic erythroblast' | cell type, phenotype | Transcription profiling by array of differentiating primary primitive and definitive mouse red blood cells |
3 | | Spry2 | 'human chorionic gonadotropin; 5 International Unit' vs 'none' in 'bER knockout' | compound, genotype | Laser Capture Microdissection isolation of preovulatory granulosa cells from WT and bERKO ovaries |
2.8 | | Spry2 | 'adult definitive erythroid cell' vs 'primitive erythroid cell' in 'proerythroblast' | cell type, phenotype | Transcription profiling by array of differentiating primary primitive and definitive mouse red blood cells |
-2.7 | | Spry2 | 'induced neuronal cell' vs 'pluripotent embryonic stem cell' | phenotype | Transcription profiling by high throughput sequencing of retinoic acid-differentiated neuronal cells compared to nondifferentiated pluripotent embryonic stem cells |
-2.7 | | Spry2 | 'CD4-positive T cell' vs 'CD8-positive T cell' in 'Egr2-GFP knockin; Egr2-GFP high' | cell type, genotype, phenotype | RNAseq analysis of CD4 and CD8 T cells in response to vaccinia virus infection |
-2.7 | | Spry2 | 'Mxd1 knockdown by siRNA' vs 'wild type' at '1 day' | phenotype, time | 3' RNA-seq of differentiating (brown) mouse subcutaneous SVF cells upon knockdown of Zfp521, Fhl1, or Mxd1 |
-2.7 | | Spry2 | 'Fhl1 knockdown by siRNA' vs 'wild type' at '1 day' | phenotype, time | 3' RNA-seq of differentiating (brown) mouse subcutaneous SVF cells upon knockdown of Zfp521, Fhl1, or Mxd1 |
2.6 | | Spry2 | 'Id2_Id3_double knockout' vs 'wild type' in 'CD4+TCRb+CD8– cell; thymus' | cell type, genotype, organism part | Transcription profiling by high throughput sequencing of Id-proteins (Id2 and Id3) gene knockout cells |
-2.5 | | Spry2 | 'trichostatin A and LIF' at '6 hour' vs 'none' at '0 hour' | compound, time | Transcription profiling of mouse embryonic stem cell line CGR8 grown in presence of Leukemia Inhibitory Factor and treated with trichostatin A |
2.4 | | Spry2 | 'bER knockout' vs 'wild type' in 'human chorionic gonadotropin; 5 International Unit' | compound, genotype | Laser Capture Microdissection isolation of preovulatory granulosa cells from WT and bERKO ovaries |
-2.3 | | Spry2 | 'trichostatin A and LIF' at '12 hour' vs 'none' at '0 hour' | compound, time | Transcription profiling of mouse embryonic stem cell line CGR8 grown in presence of Leukemia Inhibitory Factor and treated with trichostatin A |
-2.2 | | Spry2 | 'lipopolysaccharide; 10 nanogram per milliliter' vs 'none' in 'primary cell line; MEF2C/D knockout' | cell line, compound, genotype | Bulk RNA-seq of wild type and MEF2A or MEF2C/D knockout mouse bone marrow macrophages under different stimulation conditions |
-2.1 | | Spry2 | 'Lkb1 -/- Pten-/-' vs 'wild type' | genotype | Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated Pdl1 Expression: Epithelial Cells |
2.1 | | Spry2 | 'tumor' vs 'normal' in 'liver' | clinical information, organism part | Premature termination of in vivo reprogramming leads to cancer development through altered epigenetic regulation [array] |
2.1 | | Spry2 | 'renin-expression' vs 'control' | phenotype | Expression data from mouse bone marrow cells expressing renin driven expression of green fluorescent protein. |
-2 | | Spry2 | 'induced neural stem cell' vs 'neural stem cell' | cell type | Gene expression profile of mouse induced neural stem cells |
-2 | | Spry2 | 'none; wasp knockout' vs 'none; wild type' | compound, genotype | Transcription profiling of bone marrow–derived mast cells from WASP-deficient mice after stimulation with kit ligand |
-1.9 | | Spry2 | 'MG132; 1 micromolar' vs 'DMSO' in 'CHOP-/-' | compound, genotype | Microarray to find CHOP dependent genes in response to proteasome inhibition |
-1.9 | | Spry2 | 'pkd1 knockout' vs 'wild type' in 'presence of fluid flow' | genotype, stimulus | Transcription profiling by array of mouse kidney epithelial cells from pkd1 knockout and wild type in response to fluid flow |
-1.9 | | Spry2 | 'damaged by neuropathy' vs 'control' | sampling site | Transcriptional profiling of damaged and adjacent but intact dorsal root ganglia neurons against DRG cells from contralacteral control regions from mice with neuropathy |
-1.8 | | Spry2 | 'PF-04691502–resistant cell; 1 micromolar; PF-04691502 removed for 48 hours' vs 'parental AKP cell; dimethyl sulfoxide' | compound, phenotype | Resistance to PI3K/mTOR inhibitor PF-04691502 in KRAS mutant colorectal cancer models reveals a sensitivity to combination with EGFR inhibition |
-1.8 | | Spry2 | 'neurosphere in differentiation medium; 12 day' vs 'neurosphere; 0 day' in 'Cstb knockout' | genotype, growth condition, time | Transcriptome analysis of neurospheres derived from Cstb-KO mouse embryo brains during differentiation |
-1.8 | | Spry2 | 'lipopolysaccharide; 10 nanogram per milliliter and prostaglandin E2; 1 micromolar' vs 'none' in 'primary cell line; MEF2C/D knockout' | cell line, compound, genotype | Bulk RNA-seq of wild type and MEF2A or MEF2C/D knockout mouse bone marrow macrophages under different stimulation conditions |
-1.8 | | Spry2 | 'granulocyte' vs 'hemopoietic stem cell' | cell type | Gene expression data from mouse hemopoietic stem cells (LSKs), promyelocytes, myelocytes and granulocytes. |
-1.7 | | Spry2 | 'neurosphere in differentiation medium; 12 day' vs 'neurosphere; 0 day' in 'wild type genotype' | genotype, growth condition, time | Transcriptome analysis of neurospheres derived from Cstb-KO mouse embryo brains during differentiation |
-1.7 | | Spry2 | 'neurosphere in differentiation medium; 5 day' vs 'neurosphere; 0 day' in 'Cstb knockout' | genotype, growth condition, time | Transcriptome analysis of neurospheres derived from Cstb-KO mouse embryo brains during differentiation |
-1.7 | | Spry2 | 'neurosphere in differentiation medium; 1 day' vs 'neurosphere; 0 day' in 'wild type genotype' | genotype, growth condition, time | Transcriptome analysis of neurospheres derived from Cstb-KO mouse embryo brains during differentiation |
-1.7 | | Spry2 | 'neurosphere in differentiation medium; 1 day' vs 'neurosphere; 0 day' in 'Cstb knockout' | genotype, growth condition, time | Transcriptome analysis of neurospheres derived from Cstb-KO mouse embryo brains during differentiation |
1.7 | | Spry2 | 'interferon alpha' vs 'none' | compound | Type I and II Interferon-Stimulated Genes in Murine Primary Bone Marrow Macrophages |
-1.7 | | Spry2 | 'adipogenic' vs 'non-adipogenic' | phenotype | Transcription profiling by array of mouse sublines of Swiss 3T3 fibroblasts with varying potential for adipogenesis |
1.7 | | Spry2 | 'hepatocyte-derived proliferative ducts (hepPDs)' vs 'biliary-derived proliferative ducts (bilDP)' | cell type | Transcription profiling by high throughput sequencing of hepatocyte-derived progenitors cells in a mouse model of oval cell activation |
-1.7 | | Spry2 | 'acute oropharyngeal candidiasis' vs 'healthy' in wild type mice | compound, disease, genotype, sex | Transcription profiling by array of antibody blockade of IL-17-family cytokines in immunity to acute murine oral mucosal candidiasis |
-1.6 | | Spry2 | 'PF-04691502–resistant cell; 1 micromolar; PF-04691502' vs 'parental AKP cell; dimethyl sulfoxide' | compound, phenotype | Resistance to PI3K/mTOR inhibitor PF-04691502 in KRAS mutant colorectal cancer models reveals a sensitivity to combination with EGFR inhibition |
-1.6 | | Spry2 | 'Nrl-/-' vs 'wild type' | genotype | Next Generation Sequencing Facilitates Quantitative Analysis of Wild Type and Nrl-/- Retinal Transcriptomes |
1.6 | | Spry2 | 'Salmonella enterica serovar Typhimurium' vs 'control' in 'derived macrophage from E14 Traf2 mutant cell line' | clinical information, infect | Gene expression profiles of mouse embryonic stem cell derived macrophages infected with Salmonella typhimurium |
-1.6 | | Spry2 | 'postnatal day 60' vs 'postnatal day 1' in 'insulin-expressing immature beta cell' | cell type, developmental stage | Transcription profiling by high throughput sequencing of murine beta cells at key stages of maturation |
-1.6 | | Spry2 | 'neurosphere in differentiation medium; 5 day' vs 'neurosphere; 0 day' in 'wild type genotype' | genotype, growth condition, time | Transcriptome analysis of neurospheres derived from Cstb-KO mouse embryo brains during differentiation |
-1.6 | | Spry2 | 'interleukin-3 and interleukin-33' vs 'interleukin-3' | growth condition | Stem cell factor programs the mast cell activation phenotype |
-1.6 | | Spry2 | 'induced neural stem cell' vs 'mouse embryonic fibroblast cell' | cell type | Gene expression profile of mouse induced neural stem cells |
-1.6 | | Spry2 | 'beta(3)-adrenergic agonist Cl316,243' vs 'none' at '10 week' | age, stimulus | RNA-seq of age-associated transcriptome changes in brown adipose tissue |
1.6 | | Spry2 | 'clear cell sarcoma; Rosa26CreER' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
1.6 | | Spry2 | 'methionine- and choline-deficient, high fat diet' vs 'normal' | diet | Expression data from mouse liver treated with metformin |
-1.6 | | Spry2 | 'alpha-amanitin; maternal Ring1-Rnf+' vs 'none; maternal Ring1-Rnf+' | compound, genotype | Polycomb function during oogenesis is required for mouse early embryonic development (2-cell embryos) |
1.6 | | Spry2 | 'liver specific SMARCB1 knockout' vs 'wild type' | phenotype | TP53 is a master regulator of proteostasis in SMARCB1-deficient malignant rhabdoid tumors |
-1.6 | | Spry2 | 'cancer' vs 'normal' in 'lymph node medullary sinus macrophage' | cell type, disease | RNA Sequencing of CD169+ lymph node macrophages isolated from naïve or tumor-bearing mice |
1.6 | | Spry2 | 'lipopolysaccharide; 10 nanogram per milliliter and prostaglandin E2; 1 micromolar and interferon beta; 100 units per milliliter' vs 'none' in 'primary cell line; wild type genotype' | cell line, compound, genotype | Bulk RNA-seq of wild type and MEF2A or MEF2C/D knockout mouse bone marrow macrophages under different stimulation conditions |
-1.6 | | Spry2 | 'Mxd1 knockdown by siRNA' vs 'wild type' at '3 day' | phenotype, time | 3' RNA-seq of differentiating (brown) mouse subcutaneous SVF cells upon knockdown of Zfp521, Fhl1, or Mxd1 |
1.6 | | Spry2 | 'thermal injury' vs 'none' | injury | Microarray profiling of post-injury and uninjured mouse lung neutrophils from a thermal injury model |
-1.6 | | Spry2 | 'Stella maternal / zygotic knockout' vs 'wild type genotype' in '2-cell embryo' | developmental stage, genotype | Transcription profiling of wild type and Stella knockout oocytes, wild type and Stella maternal/zygotic knockout embryos to study to the role of Stella in early mouse development |
-1.6 | | Spry2 | 'MEF2C/D knockout' vs 'wild type genotype' in 'primary cell line; lipopolysaccharide; 10 nanogram per milliliter' | cell line, compound, genotype | Bulk RNA-seq of wild type and MEF2A or MEF2C/D knockout mouse bone marrow macrophages under different stimulation conditions |
-1.5 | | Spry2 | 'Debaryomyces hansenii' at '12 hour' vs 'none' at '0 hour' | stimulus, time | RNA seq of mouse bone marrow derived macrophages treated with Debaryomyces hansenii against untreated controls |
1.5 | | Spry2 | 'Ffar3 knockout' vs 'wild type' | genotype | Transcription profiling by high throughput sequencing of pancreatic islets isolated from free fatty acid receptor 3 knockout (Ffar3 KO) and wild type (Ffar3 WT) male mice |
-1.5 | | Spry2 | '216 hour' vs '0 hour' on 'Affymetrix Mouse430A_2 Array' | time | Transcription profiling of murine J1 embryonic stem cells undergoing a differentiation time course to study changes in transcription during stem cell differentiation |
1.5 | | Spry2 | 'K-ras mutant/Wt1-null' vs 'wild type' | genotype | Transcription profiling by array of wild type, K-ras mutant, Wt1-null, and double K-ras mutant/Wt1-null mouse embryonic fibroblasts |
1.5 | | Spry2 | 'seizure-preconditioning followed by intra-amygdala kainic acid' vs 'sham-preconditioning followed by intra-amygdala vehicle' | clinical treatment | Transcription profiling by array of mice with epileptic tolerance |
1.5 | | Spry2 | 'tumor' vs 'normal' in 'kidney' | clinical information, organism part | Premature termination of in vivo reprogramming leads to cancer development through altered epigenetic regulation [array] |
1.5 | | Spry2 | 'acute myeloid leukemia' vs 'myeloproliferative disorder' | disease | Transcription profiling by high throughput sequencing of c-KIT+ splenocytes from murine acute myeloid leukemia and myeloproliferative neoplasm |
-1.5 | | Spry2 | 'acute graft vs. host disease; T-cell depleted bone marrow + T cells transplant' vs 'normal; T-cell depleted bone marrow transplant' | disease, stimulus | RNA-Seq of lymph node fibroblastic reticular cells isolated from bone marrow transplant recipient mice with or without acute Graft-versus-host disease on day 7 or untransplanted control mice |
-1.5 | | Spry2 | 'MEF2C/D knockout' vs 'wild type genotype' in 'primary cell line; lipopolysaccharide; 10 nanogram per milliliter and prostaglandin E2; 1 micromolar' | cell line, compound, genotype | Bulk RNA-seq of wild type and MEF2A or MEF2C/D knockout mouse bone marrow macrophages under different stimulation conditions |
-1.5 | | Spry2 | 'Fhl1 knockdown by siRNA' vs 'wild type' at '3 day' | phenotype, time | 3' RNA-seq of differentiating (brown) mouse subcutaneous SVF cells upon knockdown of Zfp521, Fhl1, or Mxd1 |
1.4 | | Spry2 | '5 week' vs '1 week' in 'Jak2+/V617F; CRISPR/Cas9 mediated knockout of Dnmt3a' | genotype, time | RNA-seq of Jak2VF LSK cells transduced with Dnmt3a-Cas9-GFP lentivirus vs. emp-Cas9-GFP controls one week and five weeks post methylcellulose plating |
-1.4 | | Spry2 | '336 hour' vs '0 hour' on 'Affymetrix Mouse430A_2 Array' | time | Transcription profiling of murine V6.5 embryonic stem cells differentiating into embryoid bodies over a time-course to study changes in transcription during stem cell differentiation |
1.4 | | Spry2 | 'anti-CD3/CSA' vs 'anti-CD3' in 'cyclosporine-sensitive' | phenotype, treatment | Activating CD8 T cell clones via the T cell receptor complex in the absence and presence of cyclosporine A |
1.4 | | Spry2 | 'follicle stimulating hormone and epidermal growth factor' vs '293H control medium' | growth condition | Transcription profiling by array of mouse cumulus cells after culture with growth differentiation factor 9 or follicle stimulating hormone and epidermal growth factor |
1.4 | | Spry2 | 'sham-preconditioning followed by intra-amygdala kainic acid' vs 'sham-preconditioning followed by intra-amygdala vehicle' | clinical treatment | Transcription profiling by array of mice with epileptic tolerance |
1.4 | | Spry2 | 'K-ras mutant' vs 'wild type' | genotype | Transcription profiling by array of wild type, K-ras mutant, Wt1-null, and double K-ras mutant/Wt1-null mouse embryonic fibroblasts |
1.4 | | Spry2 | 'calorie restricted diet' vs 'normal diet' at '15 month' | age, diet | Transcription profiling by array of cochleae from mice fed a calorie-restricted diet |
-1.4 | | Spry2 | 'wild type; mature luminal' vs 'wild type; MaSC/basal' | cell type, genotype | Expression data from sorted control and Pygo2-null mouse mammary stem/basal cells |
1.4 | | Spry2 | 'Taf10-/-' vs 'wild type' | genotype | Transcription profiling by array of liver from Taf10 knock out mice |
1.4 | | Spry2 | '16 week' vs '4 week' | age | Differential gene expression in the Lacrimal gland during development and onset of xerostomia in Sjogren's syndrome-like disease of the C57BL/6.NOD-Aec1Aec2 mouse. |
-1.3 | | Spry2 | '96 hour' vs '0 hour' on 'Affymetrix Mouse430A_2 Array' | time | Transcription profiling of murine V6.5 embryonic stem cells differentiating into embryoid bodies over a time-course to study changes in transcription during stem cell differentiation |
-1.3 | | Spry2 | '14 day' vs '0 day' on 'Affymetrix Mouse430A_2 Array' | time | Transcription profiling of murine R1 embryonic stem cells differentiating into embryoid bodies over a time-course to study changes in transcription during stem cell differentiation |
-1.3 | | Spry2 | '4 day' vs '0 day' on 'Affymetrix Mouse430A_2 Array' | time | Transcription profiling of murine R1 embryonic stem cells differentiating into embryoid bodies over a time-course to study changes in transcription during stem cell differentiation |
-1.3 | | Spry2 | '3 day; osteogenesis differentiation' vs ' 0 day; control' in '2C12-pMirn378' | cell line, growth condition, time | Effect of Mirn378 overexpression on gene expression during C2C12 myogenic and BMP2-induced osteogenic differentiation |
-1.3 | | Spry2 | 'MG132; 1 micromolar' vs 'DMSO' in 'wild type' | compound, genotype | Microarray to find CHOP dependent genes in response to proteasome inhibition |
-1.3 | | Spry2 | '9 day' vs '0 day' on 'Affymetrix Mouse430A_2 Array' | time | Transcription profiling of murine R1 embryonic stem cells differentiating into embryoid bodies over a time-course to study changes in transcription during stem cell differentiation |
1.3 | | Spry2 | 'hypoxia' vs 'control' | treatment | Transcription profiling of mouse Jardine SIDS Model |
1.3 | | Spry2 | 'Alb-Cre-ERT2 / Cnot1 flox/flox' vs 'Cnot1 flox/flox' in 'none' | compound, genotype, time | RNA-seq of livers in control and Cnot1 tamoxifen-inducible liver-specific knockout mice |
-1.3 | | Spry2 | 'AZD7507; AZD5069 (at same dosage); 100 milligram per kilogram' vs 'none' | compound | RNA-seq to investigate differentially expressed genes in KPC mouse PDAC treated with CSF-1R small molecule inhibitor AZD7507 and/or the CXCR2 small molecule inhibitor AZD5069 |
1.3 | | Spry2 | 'Adjuvant System 03' vs 'PBS' in 'lymph node' at '4 hour' | organism part, stimulus, time | Expression data from draining lymph node and muscle of mice immunised with AS03 or PBS |
1.3 | | Spry2 | 'anti-IL-17A and anti-IL-17F treatment' vs 'no treatment' in 'wild type mice with acute oropharyngeal candidiasis' | compound, disease, genotype, sex | Transcription profiling by array of antibody blockade of IL-17-family cytokines in immunity to acute murine oral mucosal candidiasis |
-1.3 | | Spry2 | 'CD2314 and BIO' vs 'none' at '6 day' | age, compound | Transcription profiling of mouse embryonic stem cell line CGR8 during differentiation to mesenchymal stem cells and then adipocyte precursors |
1.3 | | Spry2 | 'RA839; Nrf2 knockout' vs 'RA839; wild type genotype' | RNA interference, compound, genotype | Characterization of RA839, a non-covalent small-molecule binder to Keap1 and selective activator of Nrf2 signalling |
-1.3 | | Spry2 | '48 hour' vs '0 hour' on 'Affymetrix Mouse430A_2 Array' | time | Transcription profiling of murine J1 embryonic stem cells undergoing a differentiation time course to study changes in transcription during stem cell differentiation |
-1.3 | | Spry2 | 'polarized with interleukin 4 and interleukin 13.' vs 'untreated' | compound, treatment | Expression data from polarized macrophages: effect of p53 |
1.3 | | Spry2 | 'p48-Cre;KrasG12D;Ela-Tgfa' vs 'wild type' | genotype | Transcription profiling by array of pancreas from KrasG12D, Ela-Tgfa and KrasG12D Ela-Tgfa mice |
-1.3 | | Spry2 | 'RAW264.7 macrophage cell line; control' vs 'bone marrow macrophage; control' | cell type, growth condition | Transcription profiling of mouse bone marrow macrophages (BMM) compared to BMM co-cultured with 4T1.2 breast cancer cells, treated with tumour cell supernatant, or RAW macrophage cell line |
1.3 | | Spry2 | 'E14_STAT3_ER; leukemia inhibitor factor; 10000 unit per milliliter' vs 'E14_STAT3_ER; none; ' | cell line, compound | Transcription profiling of mouse embryonic stem cells to identify genes regulated by STAT3 and NANOG, known differentiation inhibitors |
-1.3 | | Spry2 | 'Tet2 knockout' vs 'wild type' in 'hematopoietic progenitor cell' | cell type, genotype | Transcription profiling by high throughput sequencing of bone marrow stem and progenitor cells from Tet2 depleted mice |
-1.2 | | Spry2 | 'doxorubicin; 17.5 milligram per kilogram body weight' vs 'vehicle' in 'scramble; podocyte' | cell type, compound, genotype | Transcription profiling to identify the role of MOF in primary MEFs and differentiated podocytes in response to Adriamycin |
1.2 | | Spry2 | 'WT (VH81x transgenic Rag1-/-)' vs 'control' | genotype | Pre-BCR Signaling induce IgK Locus Accessibility by functional redistribution of Enhancer-mediated chromatin Interactions |
-1.2 | | Spry2 | 'Hmox1 homozygous knockout' vs 'wild type genotype' | genotype | Global transcriptomic profiles of blood monocytes from Hmox1 homozygous knockout mice compared to wild type controls following Mtb infection |
1.2 | | Spry2 | 'NOD' vs 'C57BL/6' in 'PBS stimulation' at '18 hour' | strain, time, treatment | Expression data from NOD and C57BL/6 mouse pancreas CD8α- Dendritic Cells (DCs) under steady-state and after in-vitro LPS stimulation |
-1.2 | | Spry2 | '36 hour' vs '0 hour' on 'Affymetrix Mouse430A_2 Array' | time | Transcription profiling of murine J1 embryonic stem cells undergoing a differentiation time course to study changes in transcription during stem cell differentiation |
1.2 | | Spry2 | 'doxycicline-mediated expression of c-Jun' vs 'control' | phenotype | Transcription profiling by array of mouse whole bone marrow after c-Jun induction |
1.2 | | Spry2 | '7-ketocholesterol' vs 'vehicle (cyclodextrin)' | compound, time | Array results for differential gene expression in 661W, a mouse cone photoreceptor-derived cell line, comparing cells incubated with vehicle controls vs. those treated with either of two 7-dehdyrocholesterol-derived oxysterols or cholesterol |
1.2 | | Spry2 | '3 hour' vs '1 hour' in 'fetal bovine serum; 10 percent' | growth condition, time | Transcriptomic changes in C3H10T1/2 cells exposed to lipid deprivation |
1.2 | | Spry2 | 'methionine- and choline-deficient, high fat diet mixed with 0.1% metformin' vs 'normal' | diet | Expression data from mouse liver treated with metformin |
-1.2 | | Spry2 | 'retinoic acid' vs 'none' in 'embryoid body' at '6 day' | age, compound, phenotype | Transcription profiling of mouse embryonic stem cell line Sox1Tv2 during neuronal differentiation |
1.2 | | Spry2 | 'mutant MyoD expression' at '24 hour' vs 'wild type MyoD expression' at '24 hour' | phenotype, time | Transcription profiling of mouse embryoic fibroblasts expressing wild type MyoD or its non-acetylatable version MyoD RRR to investigate how MyoD acetylation may contribute to differential gene activation. |
1.2 | | Spry2 | 'transgenic C3(1)-SV40Tag; 20 week' vs 'wild type; 8 week' | age, genotype | Prevention of mammary tumor progression by silencing HoxA1 via intraductal injection of nanoparticle-formulated siRNA |
-1.2 | | Spry2 | 'Ezh2 knockout' vs 'control' | genotype | Expression profiling of secondary wild type (WT) and Ezh2-null murine MLL-AF9 AML |
1.1 | | Spry2 | 'Irx3 knockout' vs 'control' at '7 day' | genetic modification, time | RNA-Seq of mouse Irx3-KO and Control ME3 cells on days 1 and 7 of adipogenic differentiation |
1.1 | | Spry2 | '129S1 allele at SNP rs50454566' vs 'wild type genotype' | genotype | RNA-Seq of mouse embryonic stem cells derived from genetically diverse inbred mouse strains with varying alleles at Lifr gene |
-1.1 | | Spry2 | 'Ddit4 knockout' vs 'wild type genotype' in 'high GLUT1 expression' | genotype, phenotype | RNA-seq analysis of normoxic and hypoxic tumor-associated macrophages from wild type or REDD1 knockout mice |
1.1 | | Spry2 | 'undifferentiated' vs 'differentiated; rosiglitazone' in 'A/J' | phenotype, stimulus, strain | RNA-seq of mouse subcutaneous SVF cells before and after differentiation with a brown fat differentiation cocktail |
1.1 | | Spry2 | 'Influenza A virus (A/Puerto Rico/8/1934(H1N1)); 4 day' vs 'mock' in 'WSB/EiJ' | infect, strain, time | Genomic profiling of collaborative cross founder mouse strains infected with respiratory viruses to discover novel transcripts and infection-related strain-specific gene and isoform expression |
-1.1 | | Spry2 | '6 day; osteogenesis differentiation' vs ' 0 day; control' in '2C12-pMirn378' | cell line, growth condition, time | Effect of Mirn378 overexpression on gene expression during C2C12 myogenic and BMP2-induced osteogenic differentiation |
-1.1 | | Spry2 | 'lung carcinoma' vs 'normal' in 'lung cell' | cell type, disease | Transcriptome analysis of isolated stormal cells and tumor epithelial cells in mouse lung cancer by RNA-Seq |
1.1 | | Spry2 | 'Adjuvant System 03' vs 'PBS' in 'lymph node' at '6 hour' | organism part, stimulus, time | Expression data from draining lymph node and muscle of mice immunised with AS03 or PBS |
-1.1 | | Spry2 | '24 hour before induction of differentiation' vs 'induction of differentiation' | compound, sampling time point | Expression Profiling of Early Myogenesis - Affymetrix Dataset |
-1.1 | | Spry2 | 'lung carcinoma' vs 'normal' in 'Epcam+CD11b-CD11c- epithelial cell' | cell type, disease | Transcriptome analysis of isolated stormal cells and tumor epithelial cells in mouse lung cancer by RNA-Seq |
-1.1 | | Spry2 | 'R6/2 transgenic' vs 'wild type' in '12 week; striatum' | age, genotype, organism part | Transcription profiling by high throughput sequencing in wild type and R6/2 mutant mouse cortex and striatum at 8 and 12 weeks. |
1.1 | | Spry2 | 'undifferentiated' vs 'differentiated; rosiglitazone' in 'AKR/J' | phenotype, stimulus, strain | RNA-seq of mouse subcutaneous SVF cells before and after differentiation with a brown fat differentiation cocktail |
-1.1 | | Spry2 | '96 hour' vs '0 hour' on 'Affymetrix Mouse430A_2 Array' | time | Transcription profiling of murine J1 embryonic stem cells undergoing a differentiation time course to study changes in transcription during stem cell differentiation |
-1.1 | | Spry2 | 'myelocyte' vs 'hemopoietic stem cell' | cell type | Gene expression data from mouse hemopoietic stem cells (LSKs), promyelocytes, myelocytes and granulocytes. |
1.1 | | Spry2 | 'stromal cell; E2' vs 'stromal cell; vehicle' | cell type, treatment | Affymetrix gene chip analysis for the whole mouse genome transcripts of epithelial and stromal cells from mouse uterine primary co-culture treated with either vehicle or E2 |
1.1 | | Spry2 | 'miR-1-133a_OSMR_tKO' vs 'miR-1-133a_dKO' | compound, genotype | Repression of OSMR and FGFR1 by miR-1/133a prevents adult cardiomyocyte dedifferentiation and cell cycle entry in the adult heart |
-1.1 | | Spry2 | 'nutlin-3a; polarized with interleukin 4 and interleukin 13.' vs 'untreated' | compound, treatment | Expression data from polarized macrophages: effect of p53 |
1.1 | | Spry2 | 'vehicle control; Nrf2 knockout' vs 'vehicle control; wild type genotype' | RNA interference, compound, genotype | Characterization of RA839, a non-covalent small-molecule binder to Keap1 and selective activator of Nrf2 signalling |
-1.1 | | Spry2 | 'extracellular vesicle; EMT cell culture medium' vs 'none' | sampling site, stimulus | Cellular and extracellular vesicle RNA sequence for E-cadherin-RFP EMT reporter system expressing mouse breast cancer cell line Py2T during EMT/MET |
-1 | | Spry2 | 'interferon gamma; 10 nanogram per milliliter and interleukin-13; 10 nanogram per milliliter' vs 'none' | compound | RNAseq of small intestinal organoids from mice treated with the cytokines IFNG, IL-13 and IL-22 for 24 hours |
-1 | | Spry2 | 'co-cultured with hematopoietic stem cell for 9 days' vs 'non co-cultured for 9 days' in 'endothelial cell; expressing AKT1' | cell type, growth condition, phenotype | Transcription profiling by high throughput sequencing of murine bone marrow endothelial cells and bone marrow stroma, in vitro and in vivo, with and without hematopoietic stem cells co-culture |
-1 | | Spry2 | '10 Gy Gray; x-ray' vs 'none' in 'tumor and stromal cell' | cell type, irradiate | RNA-seq of effector (CD43+) CD8+ T cells, CD45+ hematopoietic cells and CD45- tumor/stromal cells from mice bearing bilateral AT-3 tumors following radio-immunotherapy of which one tumor was irradiated |
1 | | Spry2 | 'Setd5 homozygous (null) knockout' vs 'Setd5 heterozygous knockout' | genotype | Transcriptional profiling of Setd5 heterozygous and knockout mouse embryonic stem cells |
-1 | | Spry2 | 'MG132; 1 micromolar' vs 'DMSO' in 'wild type' | compound, genotype | Microarray to find ATF5 dependent genes in response to proteasome inhibition |
1 | | Spry2 | 'CCl4 and diethylnitrosamine' vs 'none' in 'wild type genotype' | genotype, treatment | Gene expression accompanying the promotion of hepatocellular carcinoma by intestinal microbiota and Tlr4 in mice. |
-1 | | Spry2 | '7 day' vs '0 day' on 'Affymetrix Mouse430A_2 Array' | time | Transcription profiling of murine R1 embryonic stem cells differentiating into embryoid bodies over a time-course to study changes in transcription during stem cell differentiation |
1 | | Spry2 | "tunicamycin; 2 microgram per milliliter" vs "DMSO" in "C57BL/6J x WSB/EiJ F1 cross" | compound, strain | Transcription profiling by high throughput sequencing of mouse embryonic fibroblasts treated with tunicamycin to study the transcriptional response to endoplasmic reticulum stress |
-1 | | Spry2 | 'Duchenne muscular dystrophy' vs 'normal' | disease | RNA-seq comparison of immortalised myoblasts from dystrophic and WT mice |
-1 | | Spry2 | '168 hour' vs '0 hour' on 'Affymetrix Mouse430A_2 Array' | time | Transcription profiling of murine V6.5 embryonic stem cells differentiating into embryoid bodies over a time-course to study changes in transcription during stem cell differentiation |
-1 | | Spry2 | 'carcinoma' vs 'normal' | disease | Gene expression profile between normal mouse skin and carcinomas arising in the skin of RbF/F;K14creERTM;p107-/- mouse |
-1 | | Spry2 | 'Kit ligand' vs 'none' in 'wild type' | compound, genotype | Transcription profiling of bone marrow–derived mast cells from WASP-deficient mice after stimulation with kit ligand |
-1 | | Spry2 | '24 hour' vs '0 hour' in 'WT1-KTS' | genotype, time | EWS-WT1 Oncogene Activates a Neuronal Reprogramming Factor ASCL1 and Mediates Partial Neural Differentiation |
1 | | Spry2 | 'osteoblast culture 9 day' vs '0 day' | time | Transcription profiling by array of mouse primary neonatal osteoblasts to study the regulation of bone mineralisation |
1 | | Spry2 | 'SARS coronavirus MA15; 2 day' vs 'mock' in 'CAST/EiJ' | infect, strain, time | Genomic profiling of collaborative cross founder mouse strains infected with respiratory viruses to discover novel transcripts and infection-related strain-specific gene and isoform expression |
-1 | | Spry2 | '336 hour' vs '0 hour' on 'Affymetrix Mouse430A_2 Array' | time | Transcription profiling of murine J1 embryonic stem cells undergoing a differentiation time course to study changes in transcription during stem cell differentiation |
-1 | | Spry2 | '16 day' vs '0 day' | age | Gene expression profile of mouse differentiating embryonic stem cells (day 0, 6, 16, and 26) |
-1 | | Spry2 | 'lung carcinoma' vs 'normal' in 'CD11b+Ly6G+ neutrophil' | cell type, disease | Transcriptome analysis of isolated stormal cells and tumor epithelial cells in mouse lung cancer by RNA-Seq |
-1 | | Spry2 | 'KrasG12D extinction' vs 'sustained KrasG12D expression' in 'xenograft tumour' | growth condition, phenotype | Kras is required for pancreatic tumor maintenance through regulation of hexosamine biosynthesis and the non-oxidative pentose phosphate pathway |
1 | | Spry2 | 'Mkl1-RFP with a deletion of the SAP domain' vs 'full length Mkl1-RFP' | genotype | Transcription profiling by array of HC11 mammary epithelial cell strains stably expressing different variants of the transcriptional regulator megakaryoblastic leukemia-1 (Mkl1) |
1 | | Spry2 | 'spontaneous lung tumor' vs 'normal' | disease state, disease | Transcription profiling by array of spontaneous lung tumors in mice to compare to human non-small cell lung cancer |
1 | | Spry2 | 'InsR, Igf1R double knockout' vs 'wild type' in 'postnatal day 5' | developmental stage, genotype | Transcriptional profiling by array of mouse wild-type and Insulin receptor (InsR)/Igf1 receptor (Igf1R) double knockout mutant Sertoli cells from testis at embryonic day E17.5 and Postnatal day 5 |
-1 | | Spry2 | '216 hour' vs '0 hour' on 'Affymetrix Mouse430A_2 Array' | time | Transcription profiling of murine V6.5 embryonic stem cells differentiating into embryoid bodies over a time-course to study changes in transcription during stem cell differentiation |
-1 | | Spry2 | 'MHC II overexpression'vs 'empty retroviral vector' | phenotype | Effect of MHC II expression in pro-B cells: F6 leukaemic cell line |
-1 | | Spry2 | 'CD2314' vs 'none' at '6 day' | age, compound | Transcription profiling of mouse embryonic stem cell line CGR8 during differentiation to mesenchymal stem cells and then adipocyte precursors |
1 | | Spry2 | 'anti-IL-17F treatment' vs 'no treatment' in wild type mice with acute oropharyngeal candidiasis | compound, disease, genotype, sex | Transcription profiling by array of antibody blockade of IL-17-family cytokines in immunity to acute murine oral mucosal candidiasis |
1 | | Spry2 | 'infarct and border region of left ventricle 1 day post-myocardial infarction; C57BL/6J' vs 'left ventricle at baseline (no myocardial infarction) in the same region as the infarct in post-myocardial infarction hearts; C57BL/6J' | clinical information, strain | Expression data from C57BL/6J and MRL/MpJ hearts following acute myocardial infarction |
1 | | Spry2 | 'mutant MyoD expression' at '12 hour' vs 'wild type MyoD expression' at '12 hour' | phenotype, time | Transcription profiling of mouse embryoic fibroblasts expressing wild type MyoD or its non-acetylatable version MyoD RRR to investigate how MyoD acetylation may contribute to differential gene activation. |
-1 | | Spry2 | 'pkd1 knockout' vs 'wild type' in 'absence of fluid flow' | genotype, stimulus | Transcription profiling by array of mouse kidney epithelial cells from pkd1 knockout and wild type in response to fluid flow |
1 | | Spry2 | 'high fat diet; 30 degree celsius' vs 'chow; 23 degree celsius' in 'white adipose tissue' | diet, organism part, temperature | RNA-seq of brown and white mouse adipose tissue at thermoneutrality and high-fat diet |
1 | | Spry2 | 'bone marrow macrophage; co-cultured with breast cancer cell line 4T1.2' vs 'bone marrow macrophage; control' | cell type, growth condition | Transcription profiling of mouse bone marrow macrophages (BMM) compared to BMM co-cultured with 4T1.2 breast cancer cells, treated with tumour cell supernatant, or RAW macrophage cell line |
-1 | | Spry2 | 'VEGF120 knock-in (VEGF164 deficient)' vs 'wild type' | genotype | Transcription profiling by array of forebrain from mice expressing VEGF120 and deficient for VEGF164 |
1 | | Spry2 | 'α-GalCer; 2 microgram' vs 'none' in 'wild type genotype' | compound, genotype | CD1d-dependent immune suppression mediated by regulatory B cells through modulations of iNKT cells |